| Expression pattern: |
UP |
| Associated gene: |
AGO2, GW182 |
| Associated microRNA: |
miR-92b-3p |
| Biological function: |
promotes proliferation; promotes tumorigenesis |
| Molecular mechanism: |
circCDYL activates PI3K/AKT signaling to promote proliferation; circCDYL binds miR-92b-3p and is degraded via miR-92b-3p-dependent RISC (AGO2/GW182) rather than acting as a miRNA sponge. |
| Biological pathway or process: |
proliferation (promotes); PI3K/AKT (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
RT-qPCR; ISH (In Situ Hybridization); FISH / smFISH; Nuclear-Cytoplasmic Fractionation; RNase R Treatment; Actinomycin D / DRB Stability Assay; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; EdU Staining; In Vivo Animal Model; IHC (Immunohistochemistry); IF (Immunofluorescence); Western Blot; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circCDYL expression is associated with poorer disease-free survival (DFS) in HER2+ breast cancer patients. |
| Description: |
circCDYL is up-regulated in HER2+ breast cancer and promotes proliferation and tumorigenesis. Mechanistically, circCDYL activates PI3K/AKT signaling, and it directly binds miR-92b-3p but is degraded via a miR-92b-3p-dependent RISC (AGO2/GW182) mechanism rather than functioning as a miRNA sponge. High circCDYL expression predicts poorer DFS in HER2+ patients. |
| Confidence score: |
0.8846 |